Vol. 21 Nbr. 1, January 2011
> SIGN UP FREE
- Health related claims, the market for information, and the First Amendment.
- Truth or consequences? Commercial free speech vs. public health promotion (at the FDA).
- Commercial speech, drugs, promotion and a tailored advertisement moratorium.
- The Food and Drug Administration v. the First Amendment: a survey of recent FDA enforcement.
- Hidden truth: the perils and protection of off-label drug and medical device promotion.
- Discourse norms as default rules: structuring corporate speech to multiple stakeholders.
- A veil of tax exemption?: a proposal for the continuation of federal tax-exempt status for "nonprofit" hospitals.
- When regulation becomes personal: asserting retaliatory enforcement claims against regulatory agencies.
- Born by the woman, caught by the midwife: the case for legalizing direct-entry midwifery in all fifty states.